Kevin Charles Gorman

Director Kevin Charles Gorman sold 245,088 shares of NBIX at $154.33 for $37.8M under 10b5-1 plan; retains 511,293 shares.

Director Kevin Charles Gorman executed a scheduled sale of 245,088 shares at $154.33 on 2026-05-19 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-17, reducing his holdings to 511,293 shares from 756,381 shares. His prior five trades at NBIX show mixed near-term outcomes: three measurable sales posted 30-day returns of +14.0%, +5.3%, and -21.3%, while his cross-ticker track record across all tickers shows 8 prior sells with an average 90-day return of +1.4%. NBIX fundamentals remain solid with annual revenue growth of +21.4%, net income of $197,900,000.00, and a P/E of 23.38, though the stock currently trades at $155.50, down -4.2% from the 52-week high of $162.39. This is a scheduled, non-discretionary transaction, so timing characterization is not applicable.

Director Kevin Charles Gorman sells 106,322 NBIX shares ($13.4M) at $126.41; retains 514,596 shares; stock down 19.1% from 52-week high.

Director Kevin Charles Gorman sold 106,322 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $126.41 on 2025-08-07, representing a reduction of 17.1% of his pre-transaction holdings from 620,918 to 514,596 shares, for a total transaction value of $13,440,280.97. The company shows strong fundamentals with annual revenue growth of 24.8%, net income of $107,500,000.00 on revenue of $687,500,000.00, and a P/E of 35.32; however, the stock has declined 19.1% from its 52-week high of $153.29 and is down 7.1% over the past 30 days. Examining Gorman's timing history at NBIX specifically, his prior sales at this ticker show mixed results: a 2025-05-27 sale resulted in a 30-day return of +5.3%, while a 2025-01-27 sale saw a 90-day decline of -28.6%, yielding a 1-of-1 well-timed rate at the 90-day mark. His broader cross-ticker track record across 7 prior sells shows an average 90-day return of -28.6% and a 90-day well-timed rate of 100.00%, indicating his sells have historically preceded declines. The substantial sale dollar amount ($13.4M) and the current stock weakness relative to the 52-week range suggest this transaction warrants attention as part of the broader pattern of directional activity.

Director Kevin Charles Gorman sold 9,613 shares of NBIX at $120.38 for $1,157,211.02; stock now at $123.66.

Kevin Charles Gorman, a director of Neurocrine Biosciences, sold 9,613 shares (reducing holdings by -1.8%) at $120.38 on 2025-05-27 for $1,157,211.02. The stock currently trades at $123.66, up 15.3% over the past 30 days and 4.2% over 90 days, placing it 19.3% below its 52-week high of $153.29. Gorman's cross-ticker track record shows 6 prior sells with an average 90-day return of -28.6% and a 90% well-timed rate, though his NBIX-specific history is limited: only 1 prior sale with measurable outcomes (2025-01-27: -21.3% at 30d, -28.6% at 90d), while four earlier NBIX trades lack outcome data. The company generates $572.6M in quarterly revenue with 24.8% annual growth and $7.9M in net income, commanding a 40.02 P/E and $12.2B market cap. This modest share reduction by a director occurs within a context of his prior sales having preceded significant declines, though the recent 30-day and 90-day price appreciation since this transaction suggest this particular sale did not precede near-term weakness.

Director Kevin Gorman sold 146.1K NBIX shares at $149.46 on 2025-01-27; still holds 514.6K shares post-sale.

Kevin Gorman, a Director of Neurocrine Biosciences, sold 146.1K shares for $21.8M at $149.46, reducing his holdings by 22.1% to 514.6K shares. At the sale price, the transaction occurred 1.6% below the 52-week high of $153.15 and follows a 25.3% appreciation in the prior 90-day period. Gorman's cross-ticker track record shows 5 prior sells with an average 90-day return of +2.7% and a well-timed rate of 20.00%, indicating most of his historical sales preceded further gains rather than declines. At NBIX specifically, his prior 5 sales show mixed timing outcomes, with only 1 of 5 showing negative 90-day returns (well-timed). The company's fundamentals remain solid with +26.8% annual revenue growth and a P/E of 39.55, neither revealing red flags nor exceptional undervaluation. The sale represents a material liquidation of a concentrated position but does not establish a clear bearish signal given the insider's inconsistent timing and the stock's proximity to recent highs during a period of strong momentum.